As at Nov 5, 2025, the EXEL stock has a PE ratio of 16.41. This is based on the current EPS of $2.46 and the stock price of $40.37 per share. A decrease of 9% has been recorded in the P/E ratio compared to the average of 18.1 of the last 4 quarters.
The mean historical PE ratio of Exelixis over the last nine years is 52.77. The current 16.41 PE ratio is 69% below the historical average. In the past nine years, EXEL's PE ratio was at its highest in the Mar 2017 quarter at 722.33, with a price of $21.67 and an EPS of $0.03. The Dec 2018 quarter recorded the bottom point at 8.48, with a price of $19.67 and an EPS of $2.32.
Maximum annual increase: 235.44% in 2020
Maximum annual decrease: -85.49% in 2018
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 18.5 | -49.88% | $33.3 | $1.8 |
| 2023 | 36.91 | 31.17% | $23.99 | $0.65 |
| 2022 | 28.14 | 12.38% | $16.04 | $0.57 |
| 2021 | 25.04 | -55.09% | $18.28 | $0.73 |
| 2020 | 55.75 | 235.44% | $20.07 | $0.36 |
| 2019 | 16.62 | 95.99% | $17.62 | $1.06 |
| 2018 | 8.48 | -85.49% | $19.67 | $2.32 |
| 2017 | 58.46 | N/A | $30.4 | $0.52 |
| 2016 | N/A | N/A | $14.91 | -$0.28 |
| 2015 | N/A | N/A | $5.64 | -$0.77 |
| 2014 | N/A | N/A | $1.44 | -$1.34 |
| 2013 | N/A | N/A | $6.13 | -$1.33 |
| 2012 | N/A | N/A | $4.57 | -$0.92 |
| 2011 | 7.89 | N/A | $4.74 | $0.6 |
| 2010 | N/A | N/A | $8.21 | -$0.85 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Sep 2025 | 16.79 | -18.1% | $41.3 | $2.46 |
| Jun 2025 | 20.5 | 24.92% | $44.08 | $2.15 |
| Mar 2025 | 16.41 | -11.3% | $36.92 | $2.25 |
| Dec 2024 | 18.5 | 12.67% | $33.3 | $1.8 |
| Sep 2024 | 16.42 | -14.52% | $25.95 | $1.58 |
| Jun 2024 | 19.21 | -48.19% | $22.47 | $1.17 |
| Mar 2024 | 37.08 | 0.46% | $23.73 | $0.64 |
| Dec 2023 | 36.91 | -52.7% | $23.99 | $0.65 |
| Sep 2023 | 78.04 | 108.27% | $21.85 | $0.28 |
| Jun 2023 | 37.47 | -7.34% | $19.11 | $0.51 |
| Mar 2023 | 40.44 | 43.71% | $19.41 | $0.48 |
| Dec 2022 | 28.14 | 72.32% | $16.04 | $0.57 |
| Sep 2022 | 16.33 | -33.32% | $15.68 | $0.96 |
| Jun 2022 | 24.49 | 1.53% | $20.82 | $0.85 |
| Mar 2022 | 24.12 | -3.67% | $22.67 | $0.94 |
EXEL's current P/E ratio is lower than the 3, 5 and 10-year averages.
With a P/E of 16.41, EXEL stands below the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 25.01, Exelixis's P/E is 34% lower.
EXEL's PE ratio is lower than its peer stocks JNJ and AMGN, but it is greater than MRK's and PFE's. Exelixis's current PE ratio of 16.41 is below the average of its peers, which is 17.35.
| Stock name | PE ratio | Market cap |
|---|---|---|
| MRK Merck & Co Inc | 13.14 | $213.26B |
| PFE Pfizer Inc | 14.49 | $141.74B |
| BMY Bristol Myers Squibb Co | 15.54 | $93.93B |
| EXEL Exelixis Inc | 16.47 | $10.86B |
| JNJ Johnson & Johnson | 17.85 | $448.66B |
| AMGN Amgen Inc | 24.33 | $170.7B |
| CRIS Curis Inc | N/A | $17.87M |
EXEL stock has a price to earnings ratio of 16.41 as of Nov 5, 2025.
The 3-year average PE ratio for EXEL stock is 30.49.
The 5-year average PE ratio for EXEL stock is 35.65.
In the last nine years, the Mar 2017 quarter recorded the highest quarterly PE ratio at 722.33.
EXEL's current price to earnings ratio is 69% below its 9-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Nov 5, 2025), Exelixis's stock price is $40.37. The earnings per share for the trailing twelve months (TTM) ending Sep 2025 is $2.46. Therefore, Exelixis's P/E ratio for today is 16.41. PE RATIO(16.41) = STOCK PRICE($40.37) / TTM EPS($2.46)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.